Table 1.

Co-delivery of chemotherapeutic drug and siRNA using different nanovehicles.

Name of Drug	siRNA	Nanovehicle	Cell Line or Animal Model	Reference
Doxorubicin	si-BCL-2 siRNA	(ATRA) double grafted N,N,N-trimethyl chitosan (TMC) nanoparticles	QGY-7703 cells H-22 tumor model	[53]
Cisplatin	ABCC3-siRNA	Hybrid nanocarriers (PEG-PLA)	A549 xenograft model of NSCLC	[54]
Doxorubicin	P-gp siRNA, Bcl-2 siRNA	Biodegradable boronic-acid-modified ε-polylysine	Breast cancer cell line (MCF-7/ADR) cells	[55]
Salinomycin	siRNA	Cholesterol-loaded chitosan nanoparticles (C-SAR)	Gastric carcinoma cells (SNU-668 and SGC-791	[56]
Adriamycin	siRNAs targeting MVP and BCL2	Multifunctional Carboxymethyl chitosan nanoparticle	Esophageal squamous cell carcinoma mice model	[57]
Doxorubicin	P-gp siRNA	GSH reduction- and photoresponsive polymeric nanoparticles	MCF/ADR cells	[49]
Doxorubicin	polo-like kinase I (plk1) siRNA	Polyethylenimine-modified ATRP-fabricated Polymeric Nanoparticles	MDA-MB-231 and HeLa cells EAT Tumor-bearing mice	[58]
Methotrexate	STAT3 siRNA	Chitosan-modified MSNs	MCF7 cells and breast cancer model	[59]
Paclitaxel	siRNA against HER2 (siHER2)	Targeted nanoparticle	Breast tumor and brain tumor	[60]
Crizotinib (CRI)	Bcl-xL siRNA	Cationic liposomes	MCF-7 cells and breast cancer model	[61]